| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net cash provided by financing activities | 197 | 161 |
| Net decrease in cash and cash equivalents | -131,805 | -127,849 |
| Cash and cash equivalents at beginning of period | 169,735 | - |
| Cash and cash equivalents at end of period | 37,930 | - |
RAPT Therapeutics, Inc. (RAPT)
RAPT Therapeutics, Inc. (RAPT)